Brought to you by 
Elusys Therapeutics gets $10.3mm in Series D round; adds $11mm
18 Jul 2006
Executive Summary
Elusys Therapeutics (antibody-based treatments) raised $10.3mm through a Series D venture round consisting of preferred stock. Lead investors Invesco Private Capital and Essex Woodlands Health Ventures were joined by returning shareholders Crescendo Ventures, Eagle Advisors, and Legg Mason Emerald Fund also participated.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elusys Therapeutics gets $10.3mm in Series D round; adds $11mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice